[tabs]
[tab title=”2015″]
1. Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants. Poirot E, Vittinghoff E, Ishengoma D, Alifrangis M, Carneiro I, Hashim R, Baraka V, Mosha J, Gesase S, Chandramohan D, Gosling R.PLoS One. 2015 Nov 23;10(11):e0142414. doi: 10.1371/journal.pone.0142414. eCollection 2015.[Read more>>]
2. High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania. Baraka V, Ishengoma DS, Fransis F, Minja DT, Madebe RA, Ngatunga D, Van Geertruyden JP.Malar J. 2015 Nov 5;14:439. doi: 10.1186/s12936-015-0977-8.[Read more>>]
3. Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. WWARN Parasite Clearance Study Group, Abdulla S, Ashley EA, Bassat Q, Bethell D, Björkman A, Borrmann S, D’Alessandro U, Dahal P, Day NP, Diakite M, Djimde AA, Dondorp AM, Duong S, Edstein MD, Fairhurst RM, Faiz MA, Falade C, Flegg JA, Fogg C, Gonzalez R, Greenwood B, Guérin PJ, Guthmann JP, Hamed K, Hien TT, Htut Y, Juma E, Lim P, Mårtensson A, Mayxay M, Mokuolu OA, Moreira C, Newton P, Noedl H, Nosten F, Ogutu BR, Onyamboko MA, Owusu-Agyei S, Phyo AP, Premji Z, Price RN, Pukrittayakamee S, Ramharter M, Sagara I, Se Y, Suon S, Stepniewska K, Ward SA, White NJ, Winstanley PA.Malar J. 2015 Sep 22;14:359. doi: 10.1186/s12936-015-0874-1.[Read more>>]
4. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK/PD Study Group.BMC Med. 2015 Sep 18;13:227. doi: 10.1186/s12916-015-0456-7. Review.[Read more>>]
5. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. WWARN Artemisinin based Combination Therapy (ACT) Africa Baseline Study Group, Dahal P, d’Alessandro U, Dorsey G, Guerin PJ, Nsanzabana C, Price RN, Sibley CH, Stepniewska K, Talisuna AO.BMC Med. 2015 Sep 7;13:212. doi: 10.1186/s12916-015-0445-x. Review.[Read more>>]
6. Identification of large variation in pfcrt, pfmdr-1 and pfubp-1 markers in Plasmodium falciparum isolates from Ethiopia and Tanzania. Golassa L, Kamugisha E, Ishengoma DS, Baraka V, Shayo A, Baliraine FN, Enweji N, Erko B, Aseffa A, Choy A, Swedberg G.Malar J. 2015 Jul 8;14:264. doi: 10.1186/s12936-015-0783-3.[Read more>>]
7. The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data. Worldwide Antimalarial Resistance Network (WWARN) AL Dose Impact Study Group.Lancet Infect Dis. 2015 Jun;15(6):692-702. doi: 10.1016/S1473-3099(15)70024-1. Epub 2015 Mar 16. Review. Erratum in: Lancet Infect Dis. 2015 May;15(5):505.[Read more>>]
8. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, Mumba D, Kekre M, Yavo W, Mead D, Bouyou-Akotet M, Apinjoh T, Golassa L, Randrianarivelojosia M, Andagalu B, Maiga-Ascofare O, Amambua-Ngwa A, Tindana P, Ghansah A, MacInnis B, Kwiatkowski D, Djimde AA.J Infect Dis. 2015 Apr 15;211(8):1352-5. doi: 10.1093/infdis/jiu608. Epub 2014 Nov 2. Erratum in: J Infect Dis. 2016 Jan 15;213(2):327.[Read more>>]
9. Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Baiden R, Oduro A, Halidou T, Gyapong M, Sie A, Macete E, Abdulla S, Owusu-Agyei S, Mulokozi A, Adjei A, Sevene E, Compaoré G, Valea I, Osei I, Yawson A, Adjuik M, Akparibo R, Ogutu B, Upunda GL, Smith P, Binka F.Malar J. 2015 Apr 15;14:160. doi: 10.1186/s12936-015-0664-9.[Read more>>]
10. Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania. Shayo A, Buza J, Ishengoma DS.Malar J. 2015 Mar 29;14:135. doi: 10.1186/s12936-015-0649-8. Review.Read more>>]
11. Alternatively spliced transcripts and novel pseudogenes of the Plasmodium falciparum resistance-associated locus pfcrt detected in East African malaria patients. Gadalla NB, Malmberg M, Adam I, Oguike MC, Beshir K, Elzaki SE, Mukhtar I, Gadalla AA, Warhurst DC, Ngasala B, Mårtensson A, El-Sayed BB, Gil JP, Sutherland CJ.J Antimicrob Chemother. 2015 Jan;70(1):116-23. doi: 10.1093/jac/dku358. Epub 2014 Sep 24.[Read more>>]
12. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. Taylor SM, Parobek CM, DeConti DK, Kayentao K, Coulibaly SO, Greenwood BM, Tagbor H, Williams J, Bojang K, Njie F, Desai M, Kariuki S, Gutman J, Mathanga DP, Mårtensson A, Ngasala B, Conrad MD, Rosenthal PJ, Tshefu AK, Moormann AM, Vulule JM, Doumbo OK, Ter Kuile FO, Meshnick SR, Bailey JA, Juliano JJ.J Infect Dis. 2015 Mar 1;211(5):680-8. doi: 10.1093/infdis/jiu467. Epub 2014 Sep 1.[Read more>>]
13. Safe and efficacious artemisinin-based combination treatments for African pregnant women with malaria: a multicentre randomized control trial. Nambozi M, Mulenga M, Halidou T, Tagbor H, Mwapasa V, Phiri LK, Kalanda G, Valea I, Traore M, Mwakazanga D, Claeys Y, Schurmans C, De Crop M, Menten J, Ravinetto R, Thriemer K, Van Geertruyden JP, Mutabingwa T, D’Alessandro U; Pregact Group.Reprod Health. 2015 Jan 15;12:5. doi: 10.1186/1742-4755-12-5.[Read more>>]
[/tab]
[tab title=”2014″]
1. Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. Marwa KJ, Schmidt T, Sjögren M, Minzi OM, Kamugisha E, Swedberg G.Malar J. 2014 Nov 3;13:420. doi: 10.1186/1475-2875-13-420.[Read more>>]
2. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price RN, Mårtensson A, Rosenthal PJ, Dorsey G, Sutherland CJ, Guérin P, Davis TM, Ménard D, Adam I, Ademowo G, Arze C, Baliraine FN, Berens-Riha N, Björkman A, Borrmann S, Checchi F, Desai M, Dhorda M, Djimdé AA, El-Sayed BB, Eshetu T, Eyase F, Falade C, Faucher JF, Fröberg G, Grivoyannis A, Hamour S, Houzé S, Johnson J, Kamugisha E, Kariuki S, Kiechel JR, Kironde F, Kofoed PE, LeBras J, Malmberg M, Mwai L, Ngasala B, Nosten F, Nsobya SL, Nzila A, Oguike M, Otienoburu SD, Ogutu B, Ouédraogo JB, Piola P, Rombo L, Schramm B, Somé AF, Thwing J, Ursing J, Wong RP, Zeynudin A, Zongo I, Plowe CV, Sibley CH; ASAQ Molecular Marker Study Group; WWARN AL.Am J Trop Med Hyg. 2014 Oct;91(4):833-43. doi: 10.4269/ajtmh.14-0031. Epub 2014 Jul 21. Erratum in: Am J Trop.[Read more>>]
3. Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-infected women receiving cotrimoxazole prophylaxis: a multicenter randomized placebo-controlled trial. González R, Desai M, Macete E, Ouma P, Kakolwa MA, Abdulla S, Aponte JJ, Bulo H, Kabanywanyi AM, Katana A, Maculuve S, Mayor A, Nhacolo A, Otieno K, Pahlavan G, Rupérez M, Sevene E, Slutsker L, Vala A, Williamsom J, Menéndez C.PLoS Med. 2014 Sep 23;11(9):e1001735. doi: 10.1371/journal.pmed.1001735. eCollection 2014 Sep.[Read more>>]
4. Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: a multicentre randomized controlled trial. González R, Mombo-Ngoma G, Ouédraogo S, Kakolwa MA, Abdulla S, Accrombessi M, Aponte JJ, Akerey-Diop D, Basra A, Briand V, Capan M, Cot M, Kabanywanyi AM, Kleine C, Kremsner PG, Macete E, Mackanga JR, Massougbodgi A, Mayor A, Nhacolo A, Pahlavan G, Ramharter M, Rupérez M, Sevene E, Vala A, Zoleko-Manego R, Menéndez C.PLoS Med. 2014 Sep 23;11(9):e1001733. doi: 10.1371/journal.pmed.1001733. eCollection 2014 Sep.[Read more>>]
5. Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania. Shayo A, Mandara CI, Shahada F, Buza J, Lemnge MM, Ishengoma DS.Malar J. 2014 Sep 20;13:376. doi: 10.1186/1475-2875-13-376.[Read more>>]
6. Independent origin of plasmodium falciparum antifolate super-resistance, Uganda, Tanzania, and Ethiopia. Alifrangis M, Nag S, Schousboe ML, Ishengoma D, Lusingu J, Pota H, Kavishe RA, Pearce R, Ord R, Lynch C, Dejene S, Cox J, Rwakimari J, Minja DT, Lemnge MM, Roper C.Emerg Infect Dis. 2014 Aug;20(8):1280-6. doi: 10.3201/eid2008.131897.[Read more>>]
7. Adherence to artemether-lumefantrine drug combination: a rural community experience six years after change of malaria treatment policy in Tanzania. Minzi O, Maige S, Sasi P, Ngasala B.Malar J. 2014 Jul 10;13:267. doi: 10.1186/1475-2875-13-267.[Read more>>]
8. Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy. Maganda BA, Minzi OM, Kamuhabwa AA, Ngasala B, Sasi PG.Malar J. 2014 May 30;13:205. doi: 10.1186/1475-2875-13-205.[Read more>>]
9. High levels of sulphadoxine-pyrimethamine resistance Pfdhfr-Pfdhps quintuple mutations: a cross sectional survey of six regions in Tanzania. Matondo SI, Temba GS, Kavishe AA, Kauki JS, Kalinga A, van Zwetselaar M, Reyburn H, Kavishe RA.Malar J. 2014 Apr 21;13:152. doi: 10.1186/1475-2875-13-152.[Read more>>]
[/tab]
[tab title=”2013″]
1. Trends in chloroquine resistance marker, Pfcrt-K76T mutation ten years after chloroquine withdrawal in Tanzania. Mohammed A, Ndaro A, Kalinga A, Manjurano A, Mosha JF, Mosha DF, van Zwetselaar M, Koenderink JB, Mosha FW, Alifrangis M, Reyburn H, Roper C, Kavishe RA.Malar J. 2013 Nov 14;12:415. doi: 10.1186/1475-2875-12-415.[Read more>>]
2. Usefulness of Plasmodium falciparum-specific rapid diagnostic tests for assessment of parasite clearance and detection of recurrent infections after artemisinin-based combination therapy. Aydin-Schmidt B, Mubi M, Morris U, Petzold M, Ngasala BE, Premji Z, Björkman A, Mårtensson A.Malar J. 2013 Oct 1;12:349. doi: 10.1186/1475-2875-12-349.[Read more>>]
3. Declining burden of malaria over two decades in a rural community of Muheza district, north-eastern Tanzania. Ishengoma DS, Mmbando BP, Segeja MD, Alifrangis M, Lemnge MM, Bygbjerg IC.Malar J. 2013 Sep 22;12:338. doi: 10.1186/1475-2875-12-338.[Read more>>]
4. Adverse drug events resulting from use of drugs with sulphonamide-containing anti-malarials and artemisinin-based ingredients: findings on incidence and household costs from three districts with routine demographic surveillance systems in rural Tanzania. Njau JD, Kabanywanyi AM, Goodman CA, Macarthur JR, Kapella BK, Gimnig JE, Kahigwa E, Bloland PB, Abdulla SM, Kachur SP.Malar J. 2013 Jul 11;12:236. doi: 10.1186/1475-2875-12-236.[Read more>>]
5. Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. Staehli Hodel EM, Guidi M, Zanolari B, Mercier T, Duong S, Kabanywanyi AM, Ariey F, Buclin T, Beck HP, Decosterd LA, Olliaro P, Genton B, Csajka C.Malar J. 2013 Jul 10;12:235. doi: 10.1186/1475-2875-12-235.[Read more>>]
6.Plasmodium falciparum mutant haplotype infection during pregnancy associated with reduced birthweight, Tanzania. Minja DT, Schmiegelow C, Mmbando B, Boström S, Oesterholt M, Magistrado P, Pehrson C, John D, Salanti A, Luty AJ, Lemnge M, Theander T, Lusingu J, Alifrangis M.Emerg Infect Dis. 2013;19(9). doi: 10.3201/eid1909.130133.[Read more>>]
7. Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen. Hendriksen IC, Mtove G, Kent A, Gesase S, Reyburn H, Lemnge MM, Lindegardh N, Day NP, von Seidlein L, White NJ, Dondorp AM, Tarning J.Clin Pharmacol Ther. 2013 May;93(5):443-50. doi: 10.1038/clpt.2013.26. Epub 2013 Feb 8.[Read more>>]
8. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. Sawa P, Shekalaghe SA, Drakeley CJ, Sutherland CJ, Mweresa CK, Baidjoe AY, Manjurano A, Kavishe RA, Beshir KB, Yussuf RU, Omar SA, Hermsen CC, Okell L, Schallig HD, Sauerwein RW, Hallett RL, Bousema T.J Infect Dis. 2013 Jun 1;207(11):1637-45. doi: 10.1093/infdis/jit077. Epub 2013 Mar 6.[Read more>>]
9. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania. Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, Petzold M, Premji Z, Gil JP, Björkman A, Mårtensson A.Malar J. 2013 Mar 18;12:103. doi: 10.1186/1475-2875-12-103.[Read more>>]
10. Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Björkman A, Mårtensson A, Gil JP.J Infect Dis. 2013 Mar 1;207(5):842-7. doi: 10.1093/infdis/jis747. Epub 2012 Dec 5.[Read more>>]
11. Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Staehli Hodel EM, Csajka C, Ariey F, Guidi M, Kabanywanyi AM, Duong S, Decosterd LA, Olliaro P, Beck HP, Genton B.Antimicrob Agents Chemother. 2013 Feb;57(2):950-8. doi: 10.1128/AAC.01700-12. Epub 2012 Dec 10.[Read more>>]
12. Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria. Hendriksen IC, Maiga D, Lemnge MM, Mtove G, Gesase S, Reyburn H, Lindegardh N, Day NP, von Seidlein L, Dondorp AM, Tarning J, White NJ.Antimicrob Agents Chemother. 2013 Feb;57(2):775-83. doi: 10.1128/AAC.01349-12. Epub 2012 Nov 26.[Read more>>]
13. Use of artemether-lumefantrine to treat malaria during pregnancy: what do we know and need to know? Mutabingwa TK, Adam I.Expert Rev Anti Infect Ther. 2013 Feb;11(2):125-35. doi: 10.1586/eri.12.169.[Read more>>]
[/tab]
[tab title=”2012″]
1. Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania. Kamugisha E, Jing S, Minde M, Kataraihya J, Kongola G, Kironde F, Swedberg G.Malar J. 2012 Feb 27;11:58. doi: 10.1186/1475-2875-11-58.[Read more>>]
2. Large differences in prevalence of Pfcrt and Pfmdr1 mutations between Mwanza, Tanzania and Iganga, Uganda-a reflection of differences in policies regarding withdrawal of chloroquine? Kamugisha E, Bujila I, Lahdo M, Pello-Esso S, Minde M, Kongola G, Naiwumbwe H, Kiwuwa S, Kaddumukasa M, Kironde F, Swedberg G.Acta Trop. 2012 Feb;121(2):148-51. doi: 10.1016/j.actatropica.2011.11.004. Epub 2011 Nov 16.[Read more>>]
[/tab]
[tab title=”2011″]
1. Prevalence of single nucleotide polymorphisms in the Plasmodium falciparum multidrug resistance gene (Pfmdr-1) in Korogwe District in Tanzania before and after introduction of artemisinin-based combination therapy. Thomsen TT, Ishengoma DS, Mmbando BP, Lusingu JP, Vestergaard LS, Theander TG, Lemnge MM, Bygbjerg IC, Alifrangis M.Am J Trop Med Hyg. 2011 Dec;85(6):979-83. doi: 10.4269/ajtmh.2011.11-0071.[Read more>>]
2. Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Makanga M, Bassat Q, Falade CO, Premji ZG, Krudsood S, Hunt P, Walter V, Beck HP, Marrast AC, Cousin M, Rosenthal PJ.Am J Trop Med Hyg. 2011 Nov;85(5):793-804. doi: 10.4269/ajtmh.2011.11-0069.[Read more>>]
3. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE.Clin Infect Dis. 2011 Aug 1;53(3):224-30. doi: 10.1093/cid/cir376.[Read more>>]
4. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children .[Read more>>]
5. Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study.Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, Bergqvist Y, Gil JP, Premji Z, Mårtensson A.Malar J. 2011 Mar 16;10:64. doi: 10.1186/1475-2875-10-64.[Read more>>]
6. Detecting adenosine triphosphatase 6 (pfATP6) point mutations that may be associated with Plasmodium falciparum resistance to artemisinin: prevalence at baseline, before policy change in Uganda.Kamugisha E, Sendagire H, Kaddumukasa M, Enweji N, Gheysari F, Swedberg G, Kironde F.Tanzan J Health Res. 2011 Jan;13(1):40-7.[Read more>>]
[/tab]
[/tabs]